|
1
|
Paccez JD, Vogelsang M, Parker MI and
Zerbini LF: The receptor tyrosine kinase Axl in cancer: Biological
functions and therapeutic implications. Int J Cancer.
134:1024–1033. 2014.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Graham DK, DeRyckere D, Davies KD and Earp
HS: The TAM family: Phosphatidylserine sensing receptor tyrosine
kinases gone awry in cancer. Nat Rev Cancer. 14:769–785.
2014.PubMed/NCBI View
Article : Google Scholar
|
|
3
|
Qu X, Liu G, Zhong X, Li X and Zhang Q:
Role of AXL expression in non-small cell lung cancer. Oncol Lett.
12:5085–5091. 2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Zhang G, Wang M, Zhao H and Cui W:
Function of Axl receptor tyrosine kinase in non-small cell lung
cancer. Oncol Lett. 15:2726–2734. 2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Zhang Z, Lee JC, Lin L, Olivas V, Au V,
LaFramboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK, et al:
Activation of the AXL kinase causes resistance to EGFR-targeted
therapy in lung cancer. Nat Genet. 44:852–860. 2012.PubMed/NCBI View
Article : Google Scholar
|
|
6
|
Conacci-Sorrell M, McFerrin L and Eisenman
RN: An overview of MYC and its interactome. Cold Spring Harb
Perspect Med. 4(a014357)2014.PubMed/NCBI View Article : Google Scholar
|
|
7
|
García-Gutiérrez L, Delgado MD and León J:
MYC oncogene contributions to release of cell cycle brakes. Genes
(Basel). 10(244)2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Bretones G, Delgado MD and León J: Myc and
cell cycle control. Biochim Biophys Acta. 1849:506–516.
2015.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Singh AM and Dalton S: The cell cycle and
Myc intersect with mechanisms that regulate pluripotency and
reprogramming. Cell Stem Cell. 5:141–149. 2009.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Gómez-Casares MT, García-Alegria E,
López-Jorge CE, Ferrándiz N, Blanco R, Alvarez S, Vaqué JP,
Bretones G, Caraballo JM, Sánchez-Bailón P, et al: MYC antagonizes
the differentiation induced by imatinib in chronic myeloid leukemia
cells through downregulation of p27(KIP1.). Oncogene. 32:2239–2246.
2013.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Stine ZE, Walton ZE, Altman BJ, Hsieh AL
and Dang CV: MYC, metabolism, and cancer. Cancer Discov.
5:1024–1039. 2015.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Dang CV: MYC on the path to cancer. Cell.
149:22–35. 2012.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Hong J, Maacha S and Belkhiri A:
Transcriptional upregulation of c-MYC by AXL confers epirubicin
resistance in esophageal adenocarcinoma. Mol Oncol. 12:2191–2208.
2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Padayachee J, Daniels A, Balgobind A,
Ariatti M and Singh M: HER-2/neu and MYC gene silencing in breast
cancer: Therapeutic potential and advancement in nonviral
nanocarrier systems. Nanomedicine (Lond). 15:1437–1452.
2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Cancer Genome Atlas Network. Comprehensive
molecular portraits of human breast tumours. Nature. 490:61–70.
2012.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Gjerdrum C, Tiron C, Hoiby T, Stefansson
I, Haugen H, Sandal T, Collett K, Li S, McCormack E, Gjertsen BT,
et al: Axl is an essential epithelial-to-mesenchymal
transition-induced regulator of breast cancer metastasis and
patient survival. Proc Natl Acad Sci USA. 107:1124–1129.
2010.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Chang H, An R, Li X, Lang X, Feng J and Lv
M: Anti-Axl monoclonal antibodies attenuate the migration of
MDA-MB-231 breast cancer cells. Oncol Lett. 22(749)2021.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Meyer AS, Miller MA, Gertler FB and
Lauffenburger DA: The receptor AXL Diversifies EGFR signaling and
limits the response to EGFR-Targeted inhibitors in triple-negative
breast cancer cells. Sci Signal. 6(ra66)2013.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Khera L and Lev S: Accelerating AXL
targeting for TNBC therapy. Int J Biochem Cell Biol.
139(106057)2021.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Han S, Wang Y, Ge C, Gao M, Wang X, Wang
F, Sun L, Li S, Dong T, Dang Z, et al: Pharmaceutical inhibition of
AXL suppresses tumor growth and invasion of esophageal squamous
cell carcinoma. Exp Ther Med. 20(41)2020.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Avilla E, Guarino V, Visciano C, Liotti F,
Svelto M, Krishnamoorthy G, Franco R and Melillo RM: Activation of
TYRO3/AXL tyrosine kinase receptors in thyroid cancer. Cancer Res.
71:1792–1804. 2011.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Li J, Lu Y, Akbani R, Ju Z, Roebuck PL,
Liu W, Yang JY, Broom BM, Verhaak RG, Kane DW, et al: TCPA: A
resource for cancer functional proteomics data. Nat Methods.
10:1046–1047. 2013.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Brand TM, Iida M, Corrigan KL, Braverman
CM, Coan JP, Flanigan BG, Stein AP, Salgia R, Rolff J, Kimple RJ
and Wheeler DL: The receptor tyrosine kinase AXL mediates nuclear
translocation of the epidermal growth factor receptor. Sci Signal.
10(eaag1064)2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Holland SJ, Pan A, Franci C, Hu Y, Chang
B, Li W, Duan M, Torneros A, Yu J, Heckrodt TJ, et al: R428, a
selective small molecule inhibitor of Axl kinase, blocks tumor
spread and prolongs survival in models of metastatic breast cancer.
Cancer Res. 70:1544–1554. 2010.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Linger RM, Keating AK, Earp HS and Graham
DK: TAM receptor tyrosine kinases: Biologic functions, signaling,
and potential therapeutic targeting in human cancer. Adv Cancer
Res. 100:35–83. 2008.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Blancato J, Singh B, Liu A, Liao DJ and
Dickson RB: Correlation of amplification and overexpression of the
c-myc oncogene in high-grade breast cancer: FISH, in situ
hybridisation and immunohistochemical analyses. Br J Cancer.
90:1612–1619. 2004.PubMed/NCBI View Article : Google Scholar
|
|
28
|
He TC, Sparks AB, Rago C, Hermeking H,
Zawel L, da Costa LT, Morin PJ, Vogelstein B and Kinzler KW:
Identification of c-MYC as a target of the APC pathway. Science.
281:1509–1512. 1998.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Palomero T, Lim WK, Odom DT, Sulis ML,
Real PJ, Margolin A, Barnes KC, O'Neil J, Neuberg D, Weng AP, et
al: NOTCH1 directly regulates c-MYC and activates a
feed-forward-loop transcriptional network promoting leukemic cell
growth. Proc Natl Acad Sci USA. 103:18261–18266. 2006.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Casey SC, Baylot V and Felsher DW: The MYC
oncogene is a global regulator of the immune response. Blood.
131:2007–2015. 2018.PubMed/NCBI View Article : Google Scholar
|
